GBS (GBS) Competitors

GBS (NYSE:GBS) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.

Do analysts recommend GBS or STIM?

Neuronetics has a consensus target price of $4.67, indicating a potential upside of 36.85%. Given Neuronetics' stronger consensus rating and higher probable upside, analysts plainly believe Neuronetics is more favorable than GBS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GBS	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Neuronetics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has more risk & volatility, GBS or STIM?

GBS has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500.

Does the MarketBeat Community believe in GBS or STIM?

Neuronetics received 128 more outperform votes than GBS when rated by MarketBeat users.

Company	Underperform	Outperform
GBS	N/A	N/A
Neuronetics	Outperform Votes 128 68.45%	Underperform Votes 59 31.55%

Does the media prefer GBS or STIM?

In the previous week, GBS had 20 more articles in the media than Neuronetics. MarketBeat recorded 26 mentions for GBS and 6 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.80 beat GBS's score of -0.13 indicating that Neuronetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GBS	2 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Neutral
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of GBS or STIM?

2.8% of GBS shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 0.3% of GBS shares are owned by company insiders. Comparatively, 9.8% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is GBS or STIM more profitable?

GBS has a net margin of 0.00% compared to Neuronetics' net margin of -50.09%. GBS's return on equity of -85.64% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GBS	N/A	-85.64%	-54.42%
Neuronetics	-50.09%	-141.24%	-32.77%

Which has higher earnings and valuation, GBS or STIM?

GBS has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than GBS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GBS	$440K	49.75	-$8.31M	-$0.56	-2.63
Neuronetics	$71.35M	1.45	-$30.19M	-$1.23	-2.77

Summary

Neuronetics beats GBS on 10 of the 17 factors compared between the two stocks.